CN111655682A - 一种高活性sting蛋白激动剂化合物 - Google Patents

一种高活性sting蛋白激动剂化合物 Download PDF

Info

Publication number
CN111655682A
CN111655682A CN201980005220.4A CN201980005220A CN111655682A CN 111655682 A CN111655682 A CN 111655682A CN 201980005220 A CN201980005220 A CN 201980005220A CN 111655682 A CN111655682 A CN 111655682A
Authority
CN
China
Prior art keywords
alkylene
membered
alkyl
group
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980005220.4A
Other languages
English (en)
Other versions
CN111655682B (zh
Inventor
陈宇锋
陈凯旋
李磐
刘灿丰
王骥
邱庆崇
路杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Arnold Biomedical Technology Co ltd
Original Assignee
Hangzhou Arnold Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Arnold Biomedical Technology Co ltd filed Critical Hangzhou Arnold Biomedical Technology Co ltd
Priority to CN202011595914.9A priority Critical patent/CN112608331B/zh
Priority to CN202011587262.4A priority patent/CN112679523B/zh
Priority to CN202011586151.1A priority patent/CN112661773B/zh
Publication of CN111655682A publication Critical patent/CN111655682A/zh
Application granted granted Critical
Publication of CN111655682B publication Critical patent/CN111655682B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明提供式(I)或(II)化合物及其药物组合物，以及使用式(I)或(II)化合物预防和/或治疗免疫相关病症的方法。
Figure DDA0002455916210000011

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN201980005220.4A 2018-08-29 2019-08-22 一种高活性sting蛋白激动剂化合物 Active CN111655682B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202011595914.9A CN112608331B (zh) 2018-08-29 2019-08-22 中间体及其在合成sting蛋白激动剂化合物中的应用
CN202011587262.4A CN112679523B (zh) 2018-08-29 2019-08-22 高活性sting蛋白偶联剂偶联化合物及其应用
CN202011586151.1A CN112661773B (zh) 2018-08-29 2019-08-22 Sting蛋白激动剂偶联化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018109962310 2018-08-29
CN201810996231 2018-08-29
CN2018114070281 2018-11-23
CN201811407028 2018-11-23
PCT/CN2019/101925 WO2020042995A1 (zh) 2018-08-29 2019-08-22 一种高活性sting蛋白激动剂化合物

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202011587262.4A Division CN112679523B (zh) 2018-08-29 2019-08-22 高活性sting蛋白偶联剂偶联化合物及其应用
CN202011586151.1A Division CN112661773B (zh) 2018-08-29 2019-08-22 Sting蛋白激动剂偶联化合物
CN202011595914.9A Division CN112608331B (zh) 2018-08-29 2019-08-22 中间体及其在合成sting蛋白激动剂化合物中的应用

Publications (2)

Publication Number Publication Date
CN111655682A true CN111655682A (zh) 2020-09-11
CN111655682B CN111655682B (zh) 2024-05-31

Family

ID=69643943

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202011586151.1A Active CN112661773B (zh) 2018-08-29 2019-08-22 Sting蛋白激动剂偶联化合物
CN202011595914.9A Active CN112608331B (zh) 2018-08-29 2019-08-22 中间体及其在合成sting蛋白激动剂化合物中的应用
CN202011587262.4A Active CN112679523B (zh) 2018-08-29 2019-08-22 高活性sting蛋白偶联剂偶联化合物及其应用
CN201980005220.4A Active CN111655682B (zh) 2018-08-29 2019-08-22 一种高活性sting蛋白激动剂化合物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN202011586151.1A Active CN112661773B (zh) 2018-08-29 2019-08-22 Sting蛋白激动剂偶联化合物
CN202011595914.9A Active CN112608331B (zh) 2018-08-29 2019-08-22 中间体及其在合成sting蛋白激动剂化合物中的应用
CN202011587262.4A Active CN112679523B (zh) 2018-08-29 2019-08-22 高活性sting蛋白偶联剂偶联化合物及其应用

Country Status (9)

Country Link
US (1) US20240189320A1 (zh)
EP (1) EP3848366A4 (zh)
JP (1) JP7166028B2 (zh)
KR (1) KR102653190B1 (zh)
CN (4) CN112661773B (zh)
AU (1) AU2019331993B2 (zh)
CA (1) CA3110474C (zh)
TW (1) TWI723511B (zh)
WO (1) WO2020042995A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113195473A (zh) * 2018-12-14 2021-07-30 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7474319B2 (ja) * 2019-07-25 2024-04-24 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド ヘテロ環式アミド化合物及びその製造方法並びに使用
US11155567B2 (en) 2019-08-02 2021-10-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
CN111362878B (zh) * 2020-03-18 2023-09-19 湖南复瑞生物医药技术有限责任公司 一种4-氨基-1,3-二氢-苯并咪唑-2-酮的制备方法
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
CN114163420B (zh) * 2021-10-26 2023-01-24 中山大学附属第一医院 一种内质网高尔基体靶向小分子、偶联物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069155A2 (en) * 2004-12-21 2006-06-29 Bristol-Myers Squibb Company Inhibitors of protein arginine methyl transferases
WO2017049401A1 (en) * 2015-09-25 2017-03-30 Pharmascience Inc. New benzimidazoles derivatives as tec kinases family inhibitors
WO2017175147A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2018032104A1 (en) * 2016-08-17 2018-02-22 Pharmascience Inc. Spirocyclic containing compounds and pharmaceutical uses thereof
CN112351778A (zh) * 2018-06-28 2021-02-09 江苏恒瑞医药股份有限公司 稠合三环杂环类化合物及其治疗用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201103941A (en) * 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
JP2020536106A (ja) * 2017-10-05 2020-12-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
WO2019069270A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
WO2019069275A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited STING AGONIST ADMINISTRATION METHODS
CN110016025B (zh) * 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
WO2019134707A1 (zh) * 2018-01-08 2019-07-11 成都先导药物开发股份有限公司 一种免疫调节剂
EP3842437B1 (en) * 2018-08-24 2024-04-10 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
EP3873896A4 (en) * 2018-12-14 2022-08-31 Jiangsu Hengrui Medicine Co., Ltd. TRICYCLIC COMPOUNDS AS STING AGONISTS AND METHODS OF MANUFACTURE AND MEDICAL USES THEREOF

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069155A2 (en) * 2004-12-21 2006-06-29 Bristol-Myers Squibb Company Inhibitors of protein arginine methyl transferases
WO2017049401A1 (en) * 2015-09-25 2017-03-30 Pharmascience Inc. New benzimidazoles derivatives as tec kinases family inhibitors
WO2017175147A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2018032104A1 (en) * 2016-08-17 2018-02-22 Pharmascience Inc. Spirocyclic containing compounds and pharmaceutical uses thereof
CN112351778A (zh) * 2018-06-28 2021-02-09 江苏恒瑞医药股份有限公司 稠合三环杂环类化合物及其治疗用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113195473A (zh) * 2018-12-14 2021-07-30 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途

Also Published As

Publication number Publication date
TW202024063A (zh) 2020-07-01
TWI723511B (zh) 2021-04-01
WO2020042995A1 (zh) 2020-03-05
CN112608331B (zh) 2022-03-11
CA3110474A1 (en) 2020-03-05
CA3110474C (en) 2024-04-23
KR102653190B1 (ko) 2024-03-29
JP7166028B2 (ja) 2022-11-07
EP3848366A4 (en) 2022-03-16
AU2019331993B2 (en) 2022-06-02
CN112661773A (zh) 2021-04-16
CN112679523B (zh) 2022-03-11
CN112679523A (zh) 2021-04-20
EP3848366A1 (en) 2021-07-14
CN112608331A (zh) 2021-04-06
AU2019331993A1 (en) 2021-03-25
CN112661773B (zh) 2022-03-11
KR20210049895A (ko) 2021-05-06
US20240189320A1 (en) 2024-06-13
CN111655682B (zh) 2024-05-31
JP2021535909A (ja) 2021-12-23

Similar Documents

Publication Publication Date Title
TWI723511B (zh) 一種高活性sting蛋白激動劑化合物
CN111386275B (zh) 高活性sting蛋白激动剂
EP3766882B1 (en) Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof
CN112552295A (zh) Kras突变蛋白抑制剂
CN112513024A (zh) Tlr7/8拮抗剂及其用途
WO2022089454A1 (zh) 一种高活性Wnt通路抑制剂化合物
CN111989313A (zh) A2a和/或a2b受体拮抗剂
CN115066423A (zh) Pd-l1拮抗剂化合物
CN112313220A (zh) Pd-l1拮抗剂化合物
CN111440148B (zh) 一种腺苷受体拮抗剂的制备方法
LU505117B1 (en) A pan-KRAS inhibitor compound
LU505464B1 (en) A pan-KRAS inhibitor compound
WO2024022365A1 (zh) 一种Wnt通路抑制剂化合物
LU505620B1 (en) A pan-KRAS inhibitor compound
TWI810547B (zh) Pd-l1拮抗劑化合物
LU505465B1 (en) A pan-KRAS inhibitor compound
WO2023005894A1 (zh) 一种Wnt通路抑制剂化合物
WO2024060966A1 (zh) 一种pan-KRAS抑制剂化合物
WO2024104364A1 (zh) 一种pan-KRAS抑制剂化合物
WO2022199561A1 (zh) Hpk1激酶抑制剂化合物
TW202333697A (zh) Ｗｎｔ通路抑制劑化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 310000 Building 8, No. 1008, Longxiang street, Cangqian street, Yuhang District, Hangzhou City, Zhejiang Province

Applicant after: Hangzhou Arnold Biomedical Technology Co.,Ltd.

Address before: 310018 21st floor, building 2, 452, 6th Street, Qiantang New District, Hangzhou, Zhejiang Province

Applicant before: Hangzhou Arnold Biomedical Technology Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant